ClinicalTrials.gg
Not yet recruitingNCT07725705Updated Jul 24, 2026

SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)

A Phase 1/2 interventional study of SHR2554 combined with Liposomal Mitoxantrone in PTCL and First Line Treatment, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a single-arm, multicenter, Phase Ib/IIa study designed to explore the efficacy and safety of SHR2554 in combination with liposomal mitoxantrone for the treatment of patients with treatment-naive peripheral T-cell lymphoma (PTCL). The study is divided into a Phase Ib safety lead-in phase and a Phase IIa dose expansion phase.

02

Conditions studied

  • PTCL
  • First Line Treatment

Keywords

  • EZH2 inhibitor
  • SHR2554
  • Liposomal Mitoxantrone
  • First-line Treatment of PTCL
  • Zeprumetostat
03

In context

Lead sponsor

Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old,regardless of gender;
  2. Centrally confirmed histopathological/cytologic diagnosis of PTCL with the following subtypes:Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS);Follicular helper T (TFH) cell lymphoma of lymph nodes, including angioimmunoblastic, follicular, NOS; Enteropathy-associated T-cell lymphoma(EATL); Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)and any other PTCL subtypes deemed by the investigator to be eligible for inclusion.
  3. No prior anti-tumor therapy.
  4. There must be at least one measurable or evaluable lesion that meets the Lugano 2014 criteria for lymphoma: : Nodal lesions with major diameter greater than 1.5cm and minor diameter greater than 1.0cm as assessed by PET/CT or Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI); Or the length of extranodal lesions >1.0cm; 2)Evaluable lesions: PET-CT showed increased uptake in lymph nodes or extranodal regions (higher than liver) and imaging features consistent with lymphoma;
  5. performance status score: 0-2;
  6. Expected survival time ≥3 months;
  7. Have adequate organ and bone marrow functiont;
  8. No concurrent hemophagocytic lymphohistiocytosis (HLH). If a patient has clinically diagnosed HLH, enrollment eligibility will be determined by the investigator based on an evaluation of the patient's general physical condition following targeted anti-HLH therapy.
  9. Women of must have a negative serum pregnancy test within 7 days before the first dose of medication; Effective should be used from the time of until 6 months after the last dose of study drug.
  10. Capable of understanding the study procedures and voluntarily signing a written informed consent form (ICF).;

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with epigenetic agents before enrollment;
  2. Patients with a history of severe cardiac disease, history of radiation therapy to the mediastinal/pericardial region, cumulative anthracycline dose > 550 mg (doxorubicin equivalent), prior use of mitoxantrone, baseline (LVEF) \< 50%, or history of exposure to other cardiotoxic drugs;
  3. History of other primary aggressive that are not in remission, or have been in remission for less than 3 years;
  4. Primary central nervous system (CNS) lymphoma or secondary CNS involvement.
  5. Known allergy or to the study drugs or their related metabolites;
  6. Currently participating in another clinical study, or less than 4 weeks elapsed from the end of treatment in a previous clinical study to the planned start of study treatment;
  7. Pregnant or lactating women;
  8. Active infections;
  9. Medical History and Concurrent Conditions;
  10. History of (HIV) infection and/or Acquired Immunodeficiency Syndrome (AIDS);
  11. Patients with mental disorders or those unable to provide
  12. Any other condition deemed by the investigator to be unsuitable for study enrollment;
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    SHR2554 combined with Liposomal Mitoxantrone

    Drug: SHR2554 combined with Liposomal Mitoxantrone

Interventions

  • DrugSHR2554 combined with Liposomal Mitoxantrone

    Drug pages: ZeprumetostatStudies of ZeprumetostatZeprumetostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MitoxantroneStudies of MitoxantroneMitoxantrone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive 6 cycles of SHR2554 combined with liposomal mitoxantrone as induction therapy. All patients who achieve a complete response (CR) after induction therapy are eligible for transplantation. Patients achieving CR or partial response (PR), as well as those post-transplantation, may receive SHR2554 maintenance therapy in 28-day cycles. Maintenance therapy will continue until disease progression or other reasons for discontinuation. The maximum duration of SHR2554 administration in the maintenance phase will not exceed 24 months.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLT)

    Adverse events (AE) defined as DLT events per protocol

    Time frame: Cycle 1 (28 days)

  2. Complete response (CR) rate

    The proportion of subjects evaluated as complete response (CR) according to Lugano 2014 efficacy evaluation criteria

    Time frame: up to 6 months after enrollment

Secondary outcomes

  1. Objective response rate (ORR)

    The proportion of subjects evaluated as complete response (CR) and partial response (PR) according to Lugano 2014 efficacy evaluation criteria

    Time frame: up to 6 months after enrollment

  2. Duration of Response (DOR)

    The time from the first assessment of CR/PR to the first assessment of PD or death from any cause in the subject

    Time frame: up to 2.5 years post first treatment

  3. Duration of complete response (CR)

    The time from the first assessment of CR to the first assessment of PD or death from any cause in the subject

    Time frame: up to 2.5 years post first treatment

  4. Progression-free Survival (PFS)

    From the time subjects were enrolled to the time of disease progression (in any way) or death from any cause.

    Time frame: Up to 2.5 years

  5. Overall survival (OS)

    From the date of inclusion to date of death, irrespective of cause.

    Time frame: Up to 2.5 years

  6. Adverse events(AE)

    The safety of the drug was evaluated by NCI-CTC AE 6.0 standard. Hematologic and non-hematologic toxicity.

    Time frame: From the first day of medication to 28 days after the last dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 24, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Mar 1, 2030
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07725705
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Aug 1, 2028 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Jul 24, 2026

Study contacts

Liang Huang
Contact
huangliang@ihcams.ac.cn
+86 022-23608126

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zeprumetostat · Mitoxantrone

Start the discussion